<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011556</url>
  </required_header>
  <id_info>
    <org_study_id>12641</org_study_id>
    <secondary_id>I2Y-MC-GHFA(c)</secondary_id>
    <nct_id>NCT01011556</nct_id>
  </id_info>
  <brief_title>A Study for the Transdermal Application of Teriparatide</brief_title>
  <official_title>A Phase 2 Study for Transdermal Application of Teriparatide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TransPharma Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to help answer the following research questions:

        1. How teriparatide given using a skin patch (transferred through the skin using the
           ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a
           needle (pen injector) affects your bone density (how solid or porous your bones are).

        2. The safety of the teriparatide skin patch and any side effects that might be associated
           with it.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Teriparatide 20 micrograms (mcg) per day is currently only available as a subcutaneous (SQ)
      injection and many patients with severe osteoporosis for whom anabolic therapy with
      teriparatide is appropriate are either unwilling or physically unable to self-inject. The
      purpose of this Phase 2 study is to identify a transdermal dose or doses that will be
      comparable to the teriparatide 20 mcg SQ dose from a pharmacodynamic (PD) and safety
      standpoint for use in future Phase 3 studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months</measure>
    <time_frame>Baseline, 6 Months</time_frame>
    <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course Change of BMD Response at the Lumbar Spine</measure>
    <time_frame>Baseline to 6 Months and 12 Months</time_frame>
    <description>To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)</measure>
    <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 12 Months</time_frame>
    <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline of C-Terminal Telopeptide (CTX)</measure>
    <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 12 Months</time_frame>
    <description>C-terminal telopeptide is a marker of bone resorption.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month</measure>
    <time_frame>Baseline, 1 Month</time_frame>
    <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Convenience/Ease of Use Questionnaire (CEUQ)</measure>
    <time_frame>baseline up to 12 months</time_frame>
    <description>CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5). CEUQ is not a validated instrument.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours</measure>
    <time_frame>Baseline, 12 Months</time_frame>
    <description>Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02]. Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Urine Calcium Excretion at 6 and 12 Months</measure>
    <time_frame>Baseline, 6 Months, 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)</measure>
    <time_frame>Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months</time_frame>
    <description>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).</measure>
    <time_frame>Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels</measure>
    <time_frame>Baseline and 1, 3, 12, and 13 Months (mon)</time_frame>
    <description>Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers. Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: Area Under the Curve (AUC)</measure>
    <time_frame>Baseline, 1 Month, 3 Months, and 12 Months</time_frame>
    <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameters: Maximal Concentration (Cmax)</measure>
    <time_frame>Baseline, 1 Month, 3 Months, 12 Months</time_frame>
    <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up</measure>
    <time_frame>13 Month follow-up</time_frame>
    <description>Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up</measure>
    <time_frame>13 Month follow-up</time_frame>
    <description>Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>20 mcg Subcutaneous Teriparatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Received 20 micrograms (mcg) subcutaneously once daily in an unblinded manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mcg Transdermal Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received 30 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mcg Transdermal Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received 50 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 mcg Transdermal Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received 80 micrograms (mcg) teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous Teriparatide</intervention_name>
    <description>Administered subcutaneously once daily for 12 months</description>
    <arm_group_label>20 mcg Subcutaneous Teriparatide</arm_group_label>
    <other_name>recombinant human parathyroid hormone (rhPTH) (1-34)</other_name>
    <other_name>recombinant human teriparatide</other_name>
    <other_name>Forteo</other_name>
    <other_name>Forsteo</other_name>
    <other_name>LY333334</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal Teriparatide</intervention_name>
    <description>Administered transdermally, applied once daily for 6 hours over 12 months</description>
    <arm_group_label>30 mcg Transdermal Teriparatide</arm_group_label>
    <arm_group_label>50 mcg Transdermal Teriparatide</arm_group_label>
    <arm_group_label>80 mcg Transdermal Teriparatide</arm_group_label>
    <other_name>synthetic human parathyroid hormone (shPTH) (1-34)</other_name>
    <other_name>synthetic human teriparatide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatory, postmenopausal women.

          -  Centrally confirmed lumbar spine or femoral neck bone mineral density (BMD) T-score of
             less than or equal to -2.5.

          -  Without language barrier, cooperative, expected to return for all follow-up
             procedures, and have given informed consent after being informed of the risks,
             medications, and procedures to be used in the study.

          -  Able to use the pen-type injection delivery system and the ViaDerm Teriparatide System
             satisfactorily in the opinion of the investigator, or with the help of a family member
             or caregiver.

          -  Able to be reached by telephone for follow-up contact between visits

        Exclusion Criteria:

          -  Abnormal laboratory values for albumin and alkaline phosphatase.

          -  Laboratory values outside the ranges defined in the protocol for the following: Serum
             calcium, intact parathyroid hormone (iPTH), 25 hydroxyvitamin D, and 24-hour urine
             calcium

          -  History of diseases other than postmenopausal osteoporosis that affect bone
             metabolism, such as Paget's disease, renal osteodystrophy, osteomalacia, any secondary
             causes of osteoporosis, hypoparathyroidism, hyperparathyroidism, and intestinal
             malabsorption.

          -  History of malignant neoplasms in the 5 years prior to randomization, with the
             exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin
             that has been definitively treated. Patients with carcinoma in situ of the uterine
             cervix treated definitively more than 1 year prior to entry into the study may be
             randomized.

          -  Use of a pacemaker.

          -  Known chronic dermatological disorder, such as contact dermatitis

          -  History of allergy or sensitivity to tapes or adhesives

          -  Patients prone to bleeding with coagulopathies, such as hemophilia or
             thrombocytopenia.

          -  Patients who have an increased baseline risk of osteosarcoma, Paget's disease of the
             bone, or unexplained elevations of alkaline phosphatase; or prior external beam,
             implant radiation therapy involving the skeleton, or previous primary skeletal
             malignancy.

          -  Major fracture within the past year in the femur, tibia, humerus, or radius (with or
             without ulna).

        Treatment with:

          -  calcitonins in the 2 months prior to randomization.

          -  oral, transdermal/patch, or injectable estrogens, progestins, estrogen analogs,
             estrogen agonists, estrogen antagonists, selective estrogen receptor modulators, or
             tibolone in the 3 months prior to randomization; treatment with intravaginal estrogens
             in doses higher than 0.3 mg of conjugated equine estrogen, or the equivalent, for more
             than 3 doses per week in the 3 months prior to randomization.

          -  androgens or other anabolic steroids in the 6 months prior to randomization.

          -  fluorides in the 2 years prior to randomization. (Previous or current use of
             fluoridated water or topical dental fluoride treatments are permitted.)

          -  oral bisphosphonates for more than 2 consecutive months in the 6 months prior to
             randomization; treatment with intravenous bisphosphonates in the 6 months prior to
             randomization; treatment with more than 1 cycle of intermittent oral bisphosphonates
             in the 6 months prior to randomization; or having received the last cycle of this
             intermittent oral regimen less than 4 weeks prior to screening.

          -  patients receiving intravenous zoledronic acid during the 12 months prior to
             randomization.

          -  vitamin D greater than 50,000 International Units (IU) per week or with any dose of
             calcitriol or vitamin D analogs or agonists in the 6 months prior to randomization.

          -  systemic corticosteroids in the 1 month prior to randomization or for more than 30
             days in the 1 year prior to randomization. (Ophthalmic, otic, topical, orally inhaled,
             nasally inhaled, or intra-articular corticosteroid therapy may be used without these
             restrictions.)

          -  any other drug known to significantly affect bone metabolism in the 6 months prior to
             randomization.

          -  warfarin or other coumadin anticoagulants in the 1 month prior to randomization.

          -  any investigational drug in the 1 month prior to entry into the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1128AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parnu</city>
        <zip>80010</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tallin</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tartu</city>
        <zip>50410</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esztergom</city>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gyor</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szombathely</city>
        <zip>H-9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tatabanya</city>
        <zip>2800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44158</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>03300</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Estonia</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>September 21, 2012</results_first_submitted>
  <results_first_submitted_qc>September 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2012</results_first_posted>
  <disposition_first_submitted>July 13, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age Related Osteoporosis</keyword>
  <keyword>Senile Osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>20 Mcg Subcutaneous Teriparatide</title>
          <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
        </group>
        <group group_id="P2">
          <title>30 Mcg Transdermal Teriparatide</title>
          <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="P3">
          <title>50 Mcg Transdermal Teriparatide</title>
          <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="P4">
          <title>80 Mcg Transdermal Teriparatide</title>
          <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criteria not met</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>20 Mcg Subcutaneous Teriparatide</title>
          <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
        </group>
        <group group_id="B2">
          <title>30 Mcg Transdermal Teriparatide</title>
          <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="B3">
          <title>50 Mcg Transdermal Teriparatide</title>
          <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="B4">
          <title>80 Mcg Transdermal Teriparatide</title>
          <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="57"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="7.2"/>
                    <measurement group_id="B2" value="65.0" spread="8.3"/>
                    <measurement group_id="B3" value="67.6" spread="8.4"/>
                    <measurement group_id="B4" value="65.1" spread="7.2"/>
                    <measurement group_id="B5" value="65.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latin American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexican</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spaniard</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</title>
        <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>All participants who received at least 1 dose of drug and had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using intention-to-treat (ITT) principle, last observation carried forward method and ANCOVA model.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 micrograms (mcg) teriparatide subcutaneously once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</title>
          <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model and least square (LS) means were adjusted for baseline BMD values as a covariate and pooled site and treatment as fixed effects.</description>
          <population>All participants who received at least 1 dose of drug and had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using intention-to-treat (ITT) principle, last observation carried forward method and ANCOVA model.</population>
          <units>percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" lower_limit="6.867" upper_limit="8.730"/>
                    <measurement group_id="O2" value="0.63" lower_limit="-0.321" upper_limit="1.578"/>
                    <measurement group_id="O3" value="0.32" lower_limit="-0.657" upper_limit="1.287"/>
                    <measurement group_id="O4" value="1.63" lower_limit="0.739" upper_limit="2.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A noninferiority margin of 3.5% was used.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-7.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.489</ci_lower_limit>
            <ci_upper_limit>-5.851</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A noninferiority margin of 3.5% was used.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-7.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.822</ci_lower_limit>
            <ci_upper_limit>-6.144</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>A noninferiority margin of 3.5% was used.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-6.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.448</ci_lower_limit>
            <ci_upper_limit>-4.891</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months</title>
        <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</description>
        <time_frame>Baseline, 6 Months</time_frame>
        <population>All participants who received at least 1 dose of drug and had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using intent-to-treat principal, last observation carried forward method and ANCOVA model.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 6 Months</title>
          <description>Bone mineral density (BMD) of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar). Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</description>
          <population>All participants who received at least 1 dose of drug and had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using intent-to-treat principal, last observation carried forward method and ANCOVA model.</population>
          <units>percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.74" lower_limit="3.953" upper_limit="5.537"/>
                    <measurement group_id="O2" value="0.16" lower_limit="-0.661" upper_limit="0.983"/>
                    <measurement group_id="O3" value="0.88" lower_limit="0.051" upper_limit="1.705"/>
                    <measurement group_id="O4" value="1.19" lower_limit="0.418" upper_limit="1.957"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-4.58</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.716</ci_lower_limit>
            <ci_upper_limit>-3.452</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-3.87</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.006</ci_lower_limit>
            <ci_upper_limit>-2.727</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Analyses were performed using ANCOVA model with the baseline value as a covariate and pooled site and treatment as fixed effects.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-3.56</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.652</ci_lower_limit>
            <ci_upper_limit>-2.464</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course Change of BMD Response at the Lumbar Spine</title>
        <description>To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).</description>
        <time_frame>Baseline to 6 Months and 12 Months</time_frame>
        <population>All participants who received at least 1 dose of drug, had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using ITT principal.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Course Change of BMD Response at the Lumbar Spine</title>
          <description>To assess the time course of the treatment, the BMD data of the lumbar spine was assessed by dual energy X-ray absorptiometry (DXA) and analyzed using a mixed model repeated measures (MMRM) method, with the repeated measure occurring at each visit (for example, 6 and 12 month). BMD values are corrected data and have been standardized across the machine types (Hologic and Lunar).</description>
          <population>All participants who received at least 1 dose of drug, had at least 1 baseline and post-baseline lumbar spine BMD measure. Analysis was performed using ITT principal.</population>
          <units>percentage change in BMD</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months (n=54, 52, 51, 58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.72" lower_limit="3.927" upper_limit="5.516"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-0.630" upper_limit="1.019"/>
                    <measurement group_id="O3" value="0.78" lower_limit="-0.050" upper_limit="1.606"/>
                    <measurement group_id="O4" value="1.19" lower_limit="0.421" upper_limit="1.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months (n=52, 48, 45, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.12" lower_limit="7.181" upper_limit="9.060"/>
                    <measurement group_id="O2" value="0.62" lower_limit="-0.367" upper_limit="1.601"/>
                    <measurement group_id="O3" value="0.66" lower_limit="-0.348" upper_limit="1.663"/>
                    <measurement group_id="O4" value="1.93" lower_limit="0.989" upper_limit="2.881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for change in BMD at 6 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-4.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.687</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.663</ci_lower_limit>
            <ci_upper_limit>-3.392</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for change in BMD at 6 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-3.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.692</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.086</ci_lower_limit>
            <ci_upper_limit>-2.800</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for change in BMD at 6 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-3.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.665</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.627</ci_lower_limit>
            <ci_upper_limit>-2.430</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-value is for change in BMD at 12 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-7.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.818</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.856</ci_lower_limit>
            <ci_upper_limit>-6.151</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>p-value for change in BMD at 12 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-7.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.830</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.835</ci_lower_limit>
            <ci_upper_limit>-6.091</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>p-value is for change in BMD at 12 months</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>MMRM Model: Percentage change in BMD = treatment+baseline+pooled site+visit+treatment*visit interaction. Repeat measure occurred at each visit.</method_desc>
            <param_type>Difference in Least Square Means</param_type>
            <param_value>-6.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.802</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.510</ci_lower_limit>
            <ci_upper_limit>-4.860</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)</title>
        <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
        <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 12 Months</time_frame>
        <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 micrograms (mcg) teriparatide subcutaneously once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Procollagen Type 1 N-Terminal Propeptide (P1NP)</title>
          <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
          <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
          <units>percentage change in P1NP</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month (n=49, 53, 49, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.47" spread="65.390"/>
                    <measurement group_id="O2" value="19.29" spread="35.274"/>
                    <measurement group_id="O3" value="27.78" spread="31.064"/>
                    <measurement group_id="O4" value="42.06" spread="53.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=50, 51, 49, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.88" spread="118.745"/>
                    <measurement group_id="O2" value="35.68" spread="50.358"/>
                    <measurement group_id="O3" value="53.53" spread="64.625"/>
                    <measurement group_id="O4" value="116.34" spread="117.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=48, 49, 48, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.89" spread="228.773"/>
                    <measurement group_id="O2" value="62.99" spread="78.579"/>
                    <measurement group_id="O3" value="93.82" spread="93.575"/>
                    <measurement group_id="O4" value="221.28" spread="233.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months (n=47, 46, 43, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232.41" spread="176.557"/>
                    <measurement group_id="O2" value="72.17" spread="86.747"/>
                    <measurement group_id="O3" value="97.14" spread="98.007"/>
                    <measurement group_id="O4" value="178.02" spread="181.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.047</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline of C-Terminal Telopeptide (CTX)</title>
        <description>C-terminal telopeptide is a marker of bone resorption.</description>
        <time_frame>Baseline, 1 Month, 3 Months, 6 Months, 12 Months</time_frame>
        <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 micrograms (mcg) teriparatide subcutaneously once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline of C-Terminal Telopeptide (CTX)</title>
          <description>C-terminal telopeptide is a marker of bone resorption.</description>
          <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
          <units>percentage change in CTX</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 month (n=49, 53, 49, 60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.57" spread="64.980"/>
                    <measurement group_id="O2" value="8.05" spread="26.070"/>
                    <measurement group_id="O3" value="13.35" spread="29.384"/>
                    <measurement group_id="O4" value="21.66" spread="46.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months (n=50, 51, 49, 59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.78" spread="96.777"/>
                    <measurement group_id="O2" value="30.66" spread="42.048"/>
                    <measurement group_id="O3" value="42.40" spread="58.620"/>
                    <measurement group_id="O4" value="90.36" spread="103.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=48, 49, 48, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.36" spread="128.832"/>
                    <measurement group_id="O2" value="37.36" spread="52.875"/>
                    <measurement group_id="O3" value="68.63" spread="71.059"/>
                    <measurement group_id="O4" value="127.81" spread="152.725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months (n=47, 46, 43, 49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.52" spread="109.981"/>
                    <measurement group_id="O2" value="37.75" spread="58.035"/>
                    <measurement group_id="O3" value="61.25" spread="60.862"/>
                    <measurement group_id="O4" value="114.11" spread="157.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.822</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.406</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.312</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.952</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 3 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.997</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 6 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.112</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.988</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 12 months.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month</title>
        <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
        <time_frame>Baseline, 1 Month</time_frame>
        <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 micrograms (mcg) teriparatide subcutaneously once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Serum Procollagen Type 1 C-Propeptide (P1CP) at 1 Month</title>
          <description>Procollagen Type 1 N-Terminal Propeptide (P1NP) is a marker of bone formation.</description>
          <population>All randomized participants who received at least one dose of study drug. The intent-to-treat principle was applied.</population>
          <units>percentage change in P1CP</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.10" spread="85.421"/>
                    <measurement group_id="O2" value="4.63" spread="29.694"/>
                    <measurement group_id="O3" value="12.30" spread="30.153"/>
                    <measurement group_id="O4" value="23.84" spread="44.813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon Rank Sum Test</method>
            <method_desc>Pairwise comparison p-value at 1 month.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Convenience/Ease of Use Questionnaire (CEUQ)</title>
        <description>CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5). CEUQ is not a validated instrument.</description>
        <time_frame>baseline up to 12 months</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had CEUQ assessment. Last observation was carried forward, unless the last observation was also the first completed questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Convenience/Ease of Use Questionnaire (CEUQ)</title>
          <description>CEUQ consists of 5 sections and 16 questions using a 5-point Likert scale designed to collect measures for ease of use (S1), convenience of use (S2), confidence of use (S3), fear of use (S4), and overall satisfaction with therapy (S5). CEUQ is not a validated instrument.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had CEUQ assessment. Last observation was carried forward, unless the last observation was also the first completed questionnaire.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S1-Stronly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S1-Somewhat Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S1-Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S1-Somewhat Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S1-Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S2-Strongly Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S2-Somewhat Disagree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S2-Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S2-Somewhat Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S2-Strongly Agree</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S3-Not Confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S3-Somewhat Not Confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S3-Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S3-Somewhat Confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S3-Very Confident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S4-Extremely Fearful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S4-Somewhat Fearful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S4-Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S4-Somewhat Not Fearful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S4-Not Fearful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S5-Very Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S5-Somewhat Dissatisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S5-Neutral</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S5-Somewhat Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S5-Very Satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours</title>
        <description>Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02]. Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).</description>
        <time_frame>Baseline, 12 Months</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had serum calcium measurements or adjusted serum calcium measurements at the indicated timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Calcium With and Without Adjustments for Serum Albumin From Predose to After 4 and 6 Hours</title>
          <description>Serum calcium adjusted for serum albumin levels is calculated using the following formula: Total Calcium + [(40 - albumin) x 0.02]. Analysis for serum calcium and albumin adjusted serum calcium were collected at predose, 4 hours (h) post-dose (PD) and 6 h PD at baseline and 12 months (mon).</description>
          <population>All randomized participants who received at least 1 dose of study drug and had serum calcium measurements or adjusted serum calcium measurements at the indicated timepoint.</population>
          <units>millimole/Liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline- predose; no adjustment (n=54,53,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.391" spread="0.0776"/>
                    <measurement group_id="O2" value="2.362" spread="0.0933"/>
                    <measurement group_id="O3" value="2.389" spread="0.0921"/>
                    <measurement group_id="O4" value="2.392" spread="0.0915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline- 4 h PD; no adjustment (n=55,53,51,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.432" spread="0.1191"/>
                    <measurement group_id="O2" value="2.358" spread="0.1315"/>
                    <measurement group_id="O3" value="2.403" spread="0.1160"/>
                    <measurement group_id="O4" value="2.393" spread="0.1113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline- 6 h PD; no adjustment (n=52,51,48,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.440" spread="0.1159"/>
                    <measurement group_id="O2" value="2.369" spread="0.0789"/>
                    <measurement group_id="O3" value="2.400" spread="0.1167"/>
                    <measurement group_id="O4" value="2.397" spread="0.1048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon-predose; no adjustment (n=52,47,45,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.463" spread="0.1243"/>
                    <measurement group_id="O2" value="2.427" spread="0.0977"/>
                    <measurement group_id="O3" value="2.427" spread="0.0842"/>
                    <measurement group_id="O4" value="2.432" spread="0.0937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon-4 h PD; no adjustment (n=51,46,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.516" spread="0.1815"/>
                    <measurement group_id="O2" value="2.428" spread="0.1024"/>
                    <measurement group_id="O3" value="2.430" spread="0.1199"/>
                    <measurement group_id="O4" value="2.464" spread="0.1042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon-6 h PD; no adjustment (n=50,45,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.532" spread="0.1429"/>
                    <measurement group_id="O2" value="2.426" spread="0.0866"/>
                    <measurement group_id="O3" value="2.443" spread="0.0997"/>
                    <measurement group_id="O4" value="2.467" spread="0.0959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline-predose albumin adjusted (n=53,53,50,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.363" spread="0.0811"/>
                    <measurement group_id="O2" value="2.341" spread="0.0949"/>
                    <measurement group_id="O3" value="2.376" spread="0.0807"/>
                    <measurement group_id="O4" value="2.373" spread="0.0809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline-4 h PD; albumin adjusted (n=52,52,50,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.418" spread="0.1099"/>
                    <measurement group_id="O2" value="2.348" spread="0.1283"/>
                    <measurement group_id="O3" value="2.403" spread="0.0928"/>
                    <measurement group_id="O4" value="2.386" spread="0.1045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>baseline-6 h PD; albumin adjusted (n=49,50,47,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.423" spread="0.1100"/>
                    <measurement group_id="O2" value="2.363" spread="0.0727"/>
                    <measurement group_id="O3" value="2.404" spread="0.0908"/>
                    <measurement group_id="O4" value="2.394" spread="0.0934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon- predose albumin adjusted (n=52,47,45,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.461" spread="0.0998"/>
                    <measurement group_id="O2" value="2.432" spread="0.0806"/>
                    <measurement group_id="O3" value="2.449" spread="0.0861"/>
                    <measurement group_id="O4" value="2.442" spread="0.0840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon- 4 h PD; albumin adjusted (n=51,46,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.523" spread="0.1680"/>
                    <measurement group_id="O2" value="2.438" spread="0.1022"/>
                    <measurement group_id="O3" value="2.458" spread="0.1012"/>
                    <measurement group_id="O4" value="2.482" spread="0.0962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon-6 h PD; albumin adjusted (n=52,47,45,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.547" spread="0.1236"/>
                    <measurement group_id="O2" value="2.443" spread="0.0838"/>
                    <measurement group_id="O3" value="2.481" spread="0.1044"/>
                    <measurement group_id="O4" value="2.483" spread="0.1348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Urine Calcium Excretion at 6 and 12 Months</title>
        <time_frame>Baseline, 6 Months, 12 Months</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had urine calcium measurements at the indicated timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Urine Calcium Excretion at 6 and 12 Months</title>
          <population>All randomized participants who received at least 1 dose of study drug and had urine calcium measurements at the indicated timepoint.</population>
          <units>millimole/day (mmol/day)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.45" spread="1.851"/>
                    <measurement group_id="O2" value="4.21" spread="1.766"/>
                    <measurement group_id="O3" value="4.26" spread="1.673"/>
                    <measurement group_id="O4" value="4.24" spread="1.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months (n=54, 50, 49, 56)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="4.122"/>
                    <measurement group_id="O2" value="0.70" spread="3.467"/>
                    <measurement group_id="O3" value="1.20" spread="2.768"/>
                    <measurement group_id="O4" value="1.35" spread="2.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months (n=51, 47, 41, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" spread="3.694"/>
                    <measurement group_id="O2" value="4.97" spread="2.192"/>
                    <measurement group_id="O3" value="4.80" spread="2.738"/>
                    <measurement group_id="O4" value="4.51" spread="2.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)</title>
        <description>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.</description>
        <time_frame>Pre-Dose, 30 minutes, 2 hours Post-Dose at Baseline and 12 Months</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had predose and postdose blood pressure measurements at the indicated timepoint and body position.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose and Postdose Supine and Standing SBP and DBP at Baseline (BL) and 12 Months (Mon)</title>
          <description>Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) measured at pre-dose and 30 minutes (min) and 2 hours (hr) post-dose in both the supine and standing position.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had predose and postdose blood pressure measurements at the indicated timepoint and body position.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL, supine, SBP, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.71"/>
                    <measurement group_id="O2" value="2.0" spread="10.25"/>
                    <measurement group_id="O3" value="-1.0" spread="11.59"/>
                    <measurement group_id="O4" value="-0.8" spread="10.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, supine, SBP, 2 h (n=56,56,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="13.06"/>
                    <measurement group_id="O2" value="-0.9" spread="10.97"/>
                    <measurement group_id="O3" value="-3.5" spread="9.97"/>
                    <measurement group_id="O4" value="-0.6" spread="12.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, supine, DBP, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="7.63"/>
                    <measurement group_id="O2" value="1.4" spread="7.59"/>
                    <measurement group_id="O3" value="-2.5" spread="7.50"/>
                    <measurement group_id="O4" value="-1.1" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, supine, DBP, 2 h (n=56,56,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="7.59"/>
                    <measurement group_id="O2" value="-0.8" spread="8.51"/>
                    <measurement group_id="O3" value="-3.6" spread="7.02"/>
                    <measurement group_id="O4" value="-1.6" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, supine, SBP, 30min (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="8.52"/>
                    <measurement group_id="O2" value="-2.2" spread="7.47"/>
                    <measurement group_id="O3" value="-1.1" spread="8.87"/>
                    <measurement group_id="O4" value="-2.0" spread="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, supine, SBP, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="10.71"/>
                    <measurement group_id="O2" value="-1.8" spread="11.19"/>
                    <measurement group_id="O3" value="-2.5" spread="9.54"/>
                    <measurement group_id="O4" value="-1.9" spread="10.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, supine, DBP, 30min (n=52,48,45,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="7.14"/>
                    <measurement group_id="O2" value="-1.8" spread="6.08"/>
                    <measurement group_id="O3" value="-2.1" spread="6.77"/>
                    <measurement group_id="O4" value="-1.2" spread="7.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, supine, DBP, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="6.94"/>
                    <measurement group_id="O2" value="-3.3" spread="7.79"/>
                    <measurement group_id="O3" value="-1.3" spread="6.79"/>
                    <measurement group_id="O4" value="-2.0" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, SBP, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="9.38"/>
                    <measurement group_id="O2" value="2.5" spread="8.93"/>
                    <measurement group_id="O3" value="-0.6" spread="10.65"/>
                    <measurement group_id="O4" value="-0.5" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, SBP, 2 h (n=56,56,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="11.57"/>
                    <measurement group_id="O2" value="-1.6" spread="11.03"/>
                    <measurement group_id="O3" value="-3.8" spread="10.96"/>
                    <measurement group_id="O4" value="0.0" spread="12.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, DBP, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="6.56"/>
                    <measurement group_id="O2" value="0.2" spread="8.18"/>
                    <measurement group_id="O3" value="-1.2" spread="8.34"/>
                    <measurement group_id="O4" value="-1.2" spread="7.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, DBP, 2 h (n=56,56,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="7.55"/>
                    <measurement group_id="O2" value="-2.1" spread="7.80"/>
                    <measurement group_id="O3" value="-1.1" spread="7.25"/>
                    <measurement group_id="O4" value="-1.7" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, standing, SBP, 30min(n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="10.55"/>
                    <measurement group_id="O2" value="-0.9" spread="8.41"/>
                    <measurement group_id="O3" value="0.5" spread="8.68"/>
                    <measurement group_id="O4" value="-0.8" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, standing, SBP, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="11.86"/>
                    <measurement group_id="O2" value="-0.4" spread="7.64"/>
                    <measurement group_id="O3" value="-1.3" spread="12.97"/>
                    <measurement group_id="O4" value="-0.9" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, standing, DBP, 30 min(n=51,47,44,51</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="7.12"/>
                    <measurement group_id="O2" value="-2.4" spread="6.04"/>
                    <measurement group_id="O3" value="-3.5" spread="8.09"/>
                    <measurement group_id="O4" value="1.4" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12mon, standing, DBP, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="6.93"/>
                    <measurement group_id="O2" value="-2.0" spread="7.35"/>
                    <measurement group_id="O3" value="-1.9" spread="7.70"/>
                    <measurement group_id="O4" value="0.1" spread="7.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).</title>
        <time_frame>Pre-dose, 30 minutes, 2 hours at Baseline and 12 Months</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had predose and postdose heart rate measurements at the indicated timepoint and body position.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 mcg teriparatide subcutaneously once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-dose to Postdose in Supine and Standing Heart Rate at Baseline (BL) and 12 Months (Mon).</title>
          <population>All randomized participants who received at least 1 dose of study drug and had predose and postdose heart rate measurements at the indicated timepoint and body position.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL, supine, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="5.66"/>
                    <measurement group_id="O2" value="1.7" spread="5.96"/>
                    <measurement group_id="O3" value="-0.8" spread="7.21"/>
                    <measurement group_id="O4" value="-0.6" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, supine, 2 h (n=56,56,53,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="8.01"/>
                    <measurement group_id="O2" value="0.9" spread="5.61"/>
                    <measurement group_id="O3" value="-0.8" spread="8.49"/>
                    <measurement group_id="O4" value="-0.4" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, 30 min (n=56,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="6.41"/>
                    <measurement group_id="O2" value="-1.0" spread="7.36"/>
                    <measurement group_id="O3" value="0.7" spread="6.68"/>
                    <measurement group_id="O4" value="-1.2" spread="7.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, standing, 2 h (n=56,56,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="8.03"/>
                    <measurement group_id="O2" value="-0.8" spread="8.51"/>
                    <measurement group_id="O3" value="0.5" spread="6.51"/>
                    <measurement group_id="O4" value="-1.0" spread="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon, supine, 30 min (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="4.81"/>
                    <measurement group_id="O2" value="1.4" spread="4.74"/>
                    <measurement group_id="O3" value="-0.1" spread="4.06"/>
                    <measurement group_id="O4" value="-0.2" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon, supine, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="6.74"/>
                    <measurement group_id="O2" value="1.1" spread="6.60"/>
                    <measurement group_id="O3" value="-0.3" spread="5.43"/>
                    <measurement group_id="O4" value="-0.8" spread="6.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon, standing, 30 min (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="7.35"/>
                    <measurement group_id="O2" value="0.0" spread="5.28"/>
                    <measurement group_id="O3" value="-0.7" spread="5.97"/>
                    <measurement group_id="O4" value="-0.4" spread="6.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon, standing, 2 h (n=51,47,44,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="9.03"/>
                    <measurement group_id="O2" value="0.1" spread="7.36"/>
                    <measurement group_id="O3" value="-0.4" spread="7.03"/>
                    <measurement group_id="O4" value="-0.7" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels</title>
        <description>Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers. Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).</description>
        <time_frame>Baseline and 1, 3, 12, and 13 Months (mon)</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had antibody results.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Parathyroid Hormone (PTH) Specific Antibody Levels</title>
          <description>Participants were tested for anti-recombinant teriparatide and anti-synthetic teriparatide titers. Either none were detected (ND) or antibodies were determined to be present if the teriparatide specific antibody titers were at least 1:8 (titer 1:8).</description>
          <population>All randomized participants who received at least one dose of study drug and had antibody results.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: anti-recombinant ND (n=57, 54, 53, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:anti-recombinant titer 1:8(n=57,54,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mon:anti-recombinant ND (n=54,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mon:anti-recombinant titer 1:8 (n=54,54,51,62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mon:anti-recombinant ND (n=55,52,51,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mon:anti-recombinant titer 1:8 (n=55,52,51,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon:anti-recombinant ND (n=52,48,45,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon:anti-recombinant titer 1:8 (n=52,48,45,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 mon:anti-recombinant ND (n=50,46,44,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 mon:anti-recombinant titer 1:8 (n=50,46,44,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:anti-synthetic ND (n=57,54,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline:anti-synthetic titer 1:8 (n=57,54,53,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mon:anti-synthetic ND (N=54,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mon:anti-synthetic titer 1:8 (N=54,54,51,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mon:anti-synthetic ND (n=55,52,51,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mon:anti-synthetic titer 1:8 (n=55,52,51,61)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon:anti-synthetic ND (n=52,48,45,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 mon:anti-synthetic titer 18 (n=52,48,45,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 mon:anti-synthetic ND (n=50,46,44,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>13 mon:anti-synthetic titer 1:8 (n=50,46,44,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters: Area Under the Curve (AUC)</title>
        <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
        <time_frame>Baseline, 1 Month, 3 Months, and 12 Months</time_frame>
        <population>Due to high intra-subject variability, zero participants were analyzed on this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters: Area Under the Curve (AUC)</title>
          <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
          <population>Due to high intra-subject variability, zero participants were analyzed on this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics Parameters: Maximal Concentration (Cmax)</title>
        <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
        <time_frame>Baseline, 1 Month, 3 Months, 12 Months</time_frame>
        <population>Due to high intra-subject variability, zero participants were analyzed for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics Parameters: Maximal Concentration (Cmax)</title>
          <description>Due to high intra-subject variability, data was not analyzed for this outcome measure.</description>
          <population>Due to high intra-subject variability, zero participants were analyzed for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up</title>
        <description>Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)</description>
        <time_frame>13 Month follow-up</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had edema measurements at 13 months.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>DRAIZE Edema Assessment at Baseline Through 13 Month Follow-up</title>
          <description>Severity of edema was categorized based on a 5 point scale: 0=no edema, 4=severe edema (defined as an area raised more than 1 millimeter and extending beyond area of exposure)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had edema measurements at 13 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0=no edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=very slight edema to 4=severe edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up</title>
        <description>Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)</description>
        <time_frame>13 Month follow-up</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had erythema measurements at 13 months.</population>
        <group_list>
          <group group_id="O1">
            <title>20 Mcg Subcutaneous Teriparatide</title>
            <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
          </group>
          <group group_id="O2">
            <title>30 Mcg Transdermal Teriparatide</title>
            <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O3">
            <title>50 Mcg Transdermal Teriparatide</title>
            <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
          <group group_id="O4">
            <title>80 Mcg Transdermal Teriparatide</title>
            <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
          </group>
        </group_list>
        <measure>
          <title>DRAIZE Erythema Assessment at Baseline Through 13 Month Follow-up</title>
          <description>Severity of erythema was categorized based on a 5 point scale: 0=no erythema, 4=severe erythema (defined as beet red to eschar)</description>
          <population>All randomized participants who received at least 1 dose of study drug and had erythema measurements at 13 months.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0=no erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1=very slight erythema to 4=severe erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>20 Mcg Subcutaneous Teriparatide</title>
          <description>Received 20 microgram (mcg) teriparatide subcutaneously (injected) once daily in an unblinded manner.</description>
        </group>
        <group group_id="E2">
          <title>30 Mcg Transdermal Teriparatide</title>
          <description>Received 30 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="E3">
          <title>50 Mcg Transdermal Teriparatide</title>
          <description>Received 50 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
        <group group_id="E4">
          <title>80 Mcg Transdermal Teriparatide</title>
          <description>Received 80 mcg teriparatide transdermally via a patch applied once daily. Participants were blinded to dose level.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="54"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site discolouration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalciuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

